Medication info
Nesinamet Sustained Release Tablet 25/1000 mg (Alogliptin, Metformin Hydrochloride)

Nesinamet Sustained Release Tablet 25/1000 mg (Alogliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletAlogliptin Benzoate›34mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Light yellow oval sustained release film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202302753 · Approved 2023.09.14 · Insurance code 693904000

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be adjusted according to efficacy and tolerability, without exceeding the maximum recommended daily doses of each component: 25mg of alogliptin and 2000mg of extended-release metformin hydrochloride. The initial dose of this drug should be determined based on the patient’s current treatment regimen. This drug should be taken once daily, preferably with the evening meal, to reduce gastrointestinal adverse reactions associated with metformin use, and the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 25/1000mg extended-release tablets once daily. Patients taking this drug 12.5/1000mg or 12.5/500mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin The initial dose of this drug is a total daily dose of alogliptin 25mg and metformin hydrochloride 1000mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of 2000mg to reduce gastrointestinal adverse reactions from metformin. 2. Patients treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of alogliptin 25mg and the patient’s current dose of metformin hydrochloride, based on the patient’s current treatment regimen. - For patients who cannot achieve adequate glycemic control with metformin and pioglitazone combination therapy or metformin and insulin combination therapy, the initial dose of this drug is a total daily dose of alogliptin 25mg; the initial dose of metformin hydrochloride should be determined taking into account the patient’s blood glucose level and current dose. When this drug is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if needed. - Substitution for combination therapy with alogliptin and metformin When switching from combination therapy with alogliptin and metformin to this drug, the dose of this drug should correspond to the patient’s current doses of alogliptin and metformin hydrochloride. Patients with Renal Impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment (creatinine clearance ≥60mL/min). In patients with moderate renal impairment (CKD stage 3A) whose creatinine clearance is ≥45mL/min and <60mL/min, and who do not have other conditions that may increase the risk of lactic acidosis, this drug may be used with dose adjustment as follows: - The daily dose of alogliptin is 12.5mg. - The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, and the maximum daily dose is 1000mg. If creatinine clearance falls below 45mL/min, this drug should be discontinued immediately.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication can be used in conjunction with dietary therapy and exercise therapy to improve blood sugar control in patients with type 2 diabetes. The combined action of alogliptin and metformin helps effectively lower blood sugar levels. This allows for smoother blood sugar management for patients. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be adjusted according to efficacy and tolerability, without exceeding the maximum recommended daily doses of each component: 25mg of alogliptin and 2000mg of extended-release metformin hydrochloride. The initial dose of this drug should be determined based on the patient’s current treatment regimen. This drug should be taken once daily, preferably with the evening meal, to reduce gastrointestinal adverse reactions associated with metformin use, and the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 25/1000mg extended-release tablets once daily. Patients taking this drug 12.5/1000mg or 12.5/500mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin The initial dose of this drug is a total daily dose of alogliptin 25mg and metformin hydrochloride 1000mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of 2000mg to reduce gastrointestinal adverse reactions from metformin. 2. Patients treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of alogliptin 25mg and the patient’s current dose of metformin hydrochloride, based on the patient’s current treatment regimen. - For patients who cannot achieve adequate glycemic control with metformin and pioglitazone combination therapy or metformin and insulin combination therapy, the initial dose of this drug is a total daily dose of alogliptin 25mg; the initial dose of metformin hydrochloride should be determined taking into account the patient’s blood glucose level and current dose. When this drug is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if needed. - Substitution for combination therapy with alogliptin and metformin When switching from combination therapy with alogliptin and metformin to this drug, the dose of this drug should correspond to the patient’s current doses of alogliptin and metformin hydrochloride. Patients with Renal Impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment (creatinine clearance ≥60mL/min). In patients with moderate renal impairment (CKD stage 3A) whose creatinine clearance is ≥45mL/min and <60mL/min, and who do not have other conditions that may increase the risk of lactic acidosis, this drug may be used with dose adjustment as follows: - The daily dose of alogliptin is 12.5mg. - The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, and the maximum daily dose is 1000mg. If creatinine clearance falls below 45mL/min, this drug should be discontinued immediately.

Precautions

This medication can cause severe lactic acidosis or hypoglycemia; therefore, it should not be used, especially in patients with poor kidney function or severe heart disease. Patients who are hypersensitive to alogliptin, metformin, or any component of this medication, or those who have experienced allergic reactions in the past, should not take it. Patients with moderate to severe impairment of kidney function or those with acute heart failure, acute myocardial infarction, or sepsis should not take this medication. If undergoing radiological tests using iodinated contrast agents, this medication should be temporarily discontinued before and after the test, and should be resumed only after confirming normal kidney function. This medication is not suitable for patients with type 1 diabetes, diabetic ketoacidosis, or diabetic pre-coma. Patients with severe infections or those undergoing surgery, or those with moderate to severe trauma may require insulin therapy instead of this medication. If surgical procedures are to be performed, discontinue this medication 48 hours prior to surgery, and resume only after confirming normal kidney function following the surgery. Patients with impaired liver function, those with pulmonary embolism or severe lung disease, those who consume alcohol excessively, or those with dehydration or severe gastrointestinal disorders should use caution when taking this medication. This medication lowers blood sugar levels; therefore, the risk of hypoglycemia may increase when used with other blood sugar-lowering agents, so blood sugar levels should be monitored closely. During treatment, side effects such as diarrhea, nausea, headache, back pain, and infections may occur. If symptoms are severe, consult a doctor. Women who are pregnant or may become pregnant should avoid taking this medication, and breastfeeding women should also avoid it. The elderly should undergo regular kidney function tests due to the potential for decreased kidney function and should be treated with the minimal effective dose. In case of overdose, medical monitoring and treatment are required, as lactic acidosis may occur due to metformin. This medication should be swallowed whole without chewing, breaking, or crushing, and the tablet shell may be excreted in feces, which is normal.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • upper respiratory tract infection
  • nasopharyngitis
  • diarrhea
  • hypertension
  • headache
  • low back pain
  • urinary tract infection
  • pancreatitis
Show 155 more
  • hypersensitivity reaction
  • serum sickness
  • nausea
  • vomiting
  • bloating
  • weakness
  • dyspepsia
  • abdominal discomfort
  • decreased serum vitamin B12 levels
  • anaphylaxis
  • angioedema
  • rash
  • urticaria
  • Stevens-Johnson syndrome
  • similar pemphigus
  • elevated liver enzyme levels
  • fulminant hepatic failure
  • severe joint pain with disability
  • acute pancreatitis
  • intestinal obstruction
  • interstitial nephritis
  • tendinitis
  • fractures
  • costochondritis
  • leg fractures
  • arm fractures
  • spinal fractures
  • rhabdomyolysis
  • gastric ulcer
  • exacerbation of gastritis
  • hemorrhagic gastric ulcer
  • appendicitis
  • hyperglycemia
  • worsening of diabetes
  • acidosis
  • abscess
  • infection
  • wound defects
  • thyroid carcinoma
  • lung cancer
  • pulmonary carcinoma
  • chest discomfort
  • generalized edema
  • generalized weakness
  • dyspnea
  • exacerbation of asthma
  • exacerbation of pneumonia
  • respiratory arrest
  • acute renal failure
  • kidney stones
  • renal dysfunction
  • cirrhosis
  • cholelithiasis
  • myocardial infarction
  • angina
  • loss of appetite
  • cerebral infarction
  • transient ischemic attack
  • laceration
  • exacerbation of atrial fibrillation
  • speech disorders
  • skin paresthesia
  • sensory abnormalities
  • thigh paresthesia
  • fecal incontinence
  • tremor
  • numbness
  • neuropathic pain
  • spinal stenosis
  • hemiplegia
  • skin sensory abnormalities
  • dizziness
  • lightheadedness
  • vertigo
  • ligament injury
  • arthralgia
  • fibromyalgia
  • muscle cramps
  • myalgia
  • leg weakness
  • malaise
  • trigger finger
  • plantar fasciitis
  • tendon rupture
  • arthritis
  • pruritus
  • contact dermatitis
  • keratosis
  • sclerosis
  • hyperhidrosis
  • nail disease
  • otitis externa
  • guttate psoriasis
  • rosacea
  • furunculosis
  • seborrheic dermatitis
  • conjunctivitis
  • glaucoma
  • macular degeneration
  • cataract
  • keratitis
  • retinal disease
  • retinal disorders
  • bladder inflammation
  • exacerbation of cystitis
  • frequent urination
  • neurogenic bladder
  • urethritis
  • hematuria
  • increased serum creatinine
  • cholangitis
  • fatty liver
  • increased AST
  • increased ALT
  • herpes zoster
  • herpes labialis
  • herpes virus infection
  • prostatic hyperplasia
  • benign prostatic hyperplasia
  • depression
  • hypersensitivity
  • erectile dysfunction
  • insomnia
  • sleep disorders
  • orthostatic hypotension
  • hypotension
  • tinnitus
  • acute hearing loss
  • Meniere's disease
  • unspecified ear disease
  • exacerbation of angina
  • cataract extraction
  • laceration
  • bradycardia
  • palpitations
  • cough
  • increased sputum
  • bronchospasm
  • dry cough
  • chronic obstructive pulmonary disease
  • throat irritation
  • sinusitis
  • sore throat
  • tonsillitis
  • sputum disorders
  • bronchitis
  • runny nose
  • increased blood sugar
  • hyperlipidemia
  • dyslipidemia
  • increased triglycerides
  • diabetes complications
  • chest pain
  • back pain
  • brain disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container, preferably at a temperature between 1 and 30 degrees Celsius. This helps maintain the medication's effectiveness and prevents deterioration.

Appearance and packaging

Appearance

Light yellow oval sustained release film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.